Literature DB >> 7451975

Interferon-induced resistance of fibroblasts to cytolysis mediated by natural killer cells: specificity and mechanism.

G Trinchieri, D Granato, B Perussia.   

Abstract

Interferons (IF) have been shown to have a complex regulatory effect on cell-mediated cytotoxicity. In this paper, we described our analysis of the protective effect of IF on human fibroblast target cells. Fibroblasts that have been preincubated with IF are not lysed by natural killer (NK) cells. This IF-induced protection is not observed in antibody-dependent cell-mediated cytotoxicity nor in complement-dependent lysis. Both types of leukocyte IF, viral and immune, and fibroblast IF protect fibroblasts from NK cell-mediated lysis. Electrophoretically purified viral type leukocyte IF also induces protection. Experiments of absorption of NK cells on target cell monolayers and analysis of cytotoxicity at the single-cell level in semisolid medium demonstrate that NK cells bind to both IF-treated and untreated fibroblasts but lyse only the latter. The cytotoxic ability of NK cells is inactivated after interaction with fibroblasts but not with IF-treated fibroblasts. Unlabeled normal fibroblasts, but not IF-treated fibroblasts, compete for the cytotoxicity mediated by NK cells on 51Cr-labeled target fibroblasts. Based on these findings, we propose a possible interpretation of the paradoxic existence of cells that can kill normal cells in the organism and still function in cell-mediated immunity to protect against virus-infected or tumor cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7451975

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Effect of interferons on the inhibition of human natural killers by primary monolayer cell cultures.

Authors:  M Heiskala
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

Review 2.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Natural killer activity: early days, advances, and seminal observations.

Authors:  John R Ortaldo; Robert H Wiltrout; Craig W Reynolds
Journal:  Crit Rev Oncog       Date:  2014

Review 4.  IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.

Authors:  M Hokland; P Basse; J Justesen; P Hokland
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

5.  The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.

Authors:  H Yeoman; R A Robins
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

6.  Interferon enhancement of the invasive capacity of Ewing sarcoma cells in vitro.

Authors:  G P Siegal; U P Thorgeirsson; R G Russo; D M Wallace; L A Liotta; S L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Effect of Toxoplasma infection on the sensitivity of mouse thymocytes to natural killer cells.

Authors:  T Kamiyama; M Tatsumi
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

9.  Low-dose human cytomegalovirus infection of human fibroblast cultures induces lymphokine-activated killer cell resistance: interferon-beta-mediated target cell protection does not correlate with up-regulation of HLA class I surface molecules.

Authors:  K Hamprecht; M Steinmassl
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

Review 10.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.